Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals Inc (NY: ATNM )

8.430 USD +0.130 (+1.57%)
Official Closing Price Updated: 6:38 PM EST, Jan 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 436,538
Open 8.470
Bid (Size) 8.370 (1)
Ask (Size) 8.500 (4)
Prev. Close 8.300
Today's Range 8.188 - 8.500
52wk Range 0.1570 - 13.18
Shares Outstanding 80,072,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
- Builds the collaboration utilizing Actinium's Antibody Warhead Enabling (AWE) Technology Platform with selected Astellas targeting agents 
From PR Newswire
Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial
- 100% rate of BMT and engraftment in patients receiving therapeutic dose of Iomab-B and lower rates of sepsis and sepsis related Grade ≥3 adverse events compared to patients receiving salvage... 
From PR Newswire

Performance

YTD
+7.25%
+7.25%
1 Month
-24.66%
-24.66%
3 Month
-27.14%
-27.14%
6 Month
+1774.58%
+1774.58%
1 Year
+3099.24%
+3099.24%

More News

Read More
Actinium Highlights Presence at Targeted Radiopharmaceuticals Summit
From PR Newswire
Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH
From PR Newswire
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting
From PR Newswire
Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting
From PR Newswire
Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting
From PR Newswire
Actinium Highlights Clinical Data to be Presented at the Upcoming 62nd American Society of Hematology Annual Meeting
From PR Newswire
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
From PR Newswire
Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity
From PR Newswire
Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.